PhaseV
Last verified 2026-06-12. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $65.0Mattributed |
|---|---|
| Latest round | series-a, $50.0M, 2025-05-13attributed |
| Founded | 2020 |
| Headquarters | Boston |
| Industry | bio |
| Stage | series-a |
| Website | phasevtrials.com |
PhaseV provides AI and machine learning tools that streamline clinical drug development from trial design through execution and analysis. It serves biopharma sponsors and CROs across oncology, immunology, and neurology. Its edge is causal machine learning that finds responsive patient subgroups and enables smaller, faster, lower-cost trials.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-05-13 | series-a | $50.0M | undisclosed |
Detected tech stack
cloudflare, cookieyes, doubleclick floodlight, google analytics, google tag manager, hsts, http/3, jquery 3.5.1, jsdelivr, mysql, php, wordpress
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $50.0M | attributed | news-misc named as publisher. No document URL on file. |
| Total raised $65.0M | attributed | news-misc named as publisher. No document URL on file. |
| Company existence | self-reported | phasevtrials.com, read 2026-06-12 |
| Description | self-reported | phasevtrials.com, read 2026-06-12 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.